M. McMasters

发表

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2016, Science Translational Medicine.

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

R. Soiffer, R. Joyce, Shuli Li, 2016, Blood.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

A multicenter, retrospective, case‐cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients

K. Ballen, D. Braun, D. Leffler, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Traci M. Blonquist, D. Neuberg, K. Ballen, 2018, Cancer.

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

B. Ebert, K. Ballen, D. DeAngelo, 2018, American journal of hematology.

Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor

R. Alterman, H. Shih, E. Wong, 2021, Surgical neurology international.

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

V. Boussiotis, D. Avigan, I. Politikos, 2018, Blood advances.

The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH

D. DeAngelo, J. Zwicker, A. Falanga, 2020, Journal of thrombosis and haemostasis : JTH.

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

I. Flinn, H. Deeg, F. Thol, 2021, Leukemia.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

F. Slack, D. Tenen, D. Kufe, 2017, Leukemia.

Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation.

H. Lazarus, Barbra M. Blair, M. McMasters, 2020, Blood reviews.

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

P. Pandolfi, D. Kufe, R. Joyce, 2017, Blood.

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2015 .

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

F. Slack, D. Kufe, E. Anastasiadou, 2019, British journal of haematology.

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

J. Ritz, S. Nikiforow, P. Armand, 2018, Haematologica.

MUC 1 Inhibition Leads to Decrease in PD-L 1 Levels via Up-Regulation of miRNAs

F. Slack, D. Kufe, E. Anastasiadou, 2016 .

Primary mediastinal large B-cell lymphoma: a retrospective analysis of rituximab and CHOP chemotherapy

M. McMasters, A. Novoselac, R. Levine, 2007 .

H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.

M. Warmuth, P. Greenberg, M. Maris, 2017 .

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

H. Deeg, F. Thol, P. Greenberg, 2019, Blood.

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

D. Neuberg, K. Ballen, M. Levis, 2016 .